1-苄基-2H-吡啶-3-甲酰胺 | 2288-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-苄基-2H-吡啶-3-甲酰胺
• 英文名称: 1-benzyl-nicotinamide
• 英文别名: 1-benzylnicotinamide；1-Benzyl-1,2-dihydropyridine-3-carboxamide；1-benzyl-2H-pyridine-3-carboxamide
• CAS: 2288-37-1
• 化学式: C₁₃H₁₄N₂O
• 分子量: 214.267
• InChiKey: QQYMLLWURQVAJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(氨基羰基)-1-苄基吡啶鎓氯化物 、 硼氢化钠 生成 1-苄基-2H-吡啶-3-甲酰胺
  参考文献：
  名称：

  PAGLIETTI, G.;SANNA, P.;NUVOLE, A.;SOCCOLINI, F.;ACHESON, R. M., J. CHEM. RES. MICROFICHE, 1983, N 10, 245

  摘要：

  DOI：
• 作为试剂：
  描述：

  5-nitrouridine 2',3',5'-tri-O-benzoate 在 1-苄基-2H-吡啶-3-甲酰胺 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以12%的产率得到2',3',5'-tri-O-benzoyl-5,6-dihydro-5-nitrouridine
  参考文献：
  名称：

  Reduction of Uracil Derivatives with an NADH Model, 1-Benzyl-1,4-dihydronicotinamide

  摘要：

  Among various C(5)-, N(1)-, and N(3)-substituted uracils, 1-substituted 5-nitrouracil derivatives were reduced by an NADH model, l-benzyl 1,4-dihydronicotinamide, to give 5, 6-dihydro-5-nitrouracil derivatives, the formation of which was accelerated to a large extent by the use of Mg2+ as a catalyst.

  DOI：

  10.3987/com-98-s53

文献信息

• SELECTIVE CARBON DIOXIDE REDUCTION CATALYZED BY SINGLE METAL SITES ON CARBON NITRIDE UNDER VISIBLE LIGHT IRRADIATION
  申请人：University of New Hampshire

  公开号：US20200376475A1

  公开（公告）日：2020-12-03

  A composition of a photocatalyst, a method of manufacturing the photocatalyst, and a method of chemically reducing carbon dioxide to carbon monoxide using the photocatalyst under visible-light irradiation is provided. The photocatalyst comprises a transition metal ion and graphitic carbon nitride and includes single metal sites on carbon nitride. Under visible light, the metal sites that are coordinated to nitrogen atoms get activated, without the use of additional ligands, to catalyze the reduction of carbon dioxide to selectively produce carbon monoxide. The photocatalytic reduction of carbon dioxide to carbon monoxide is highly efficient, resulting a turnover number of more than 800 for carbon monoxide production in 2 hours. The composition is useful in converting carbon dioxide into useful chemicals and carbon-based fuels. A functional model of molecular catalysts for efficient carbon dioxide reduction is also present.

  提供了一种光催化剂的组合物、制造该光催化剂的方法，以及在可见光照射下使用该光催化剂将二氧化碳化学还原为一氧化碳的方法。该光催化剂包括过渡金属离子和石墨烯碳氮，并在碳氮上包含单金属位点。在可见光下，与氮原子配位的金属位点被激活，无需额外的配体，催化将二氧化碳还原为有选择性地产生一氧化碳。将二氧化碳光催化还原为一氧化碳效率非常高，2小时内一氧化碳产量的周转数超过800。该组合物可用于将二氧化碳转化为有用的化学品和碳基燃料。同时还提供了用于高效还原二氧化碳的分子催化剂的功能模型。
• Therapeutic systems
  申请人：Enzacta R & D Limited

  公开号：US20030086933A1

  公开（公告）日：2003-05-08

  A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug. A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2.

  该化合物包括一个靶细胞特异性部分和人类NAD（P）H：醌还原酶2（NQO2）或其变体或片段或融合物或衍生物，其对给定的前药具有与NQO2基本相同的活性，或者编码该NQO2或其变体或片段或融合物或衍生物的多核苷酸。一种重组多核苷酸，包括一个靶细胞特异性启动子与编码人类NAD（P）H：醌还原酶2（NQO2）或其变体或片段或融合物或衍生物的多核苷酸可操作地连接在一起，该NQO2或其变体或片段或融合物或衍生物对于给定的前药具有与NQO2基本相同的活性。这些化合物和多核苷酸在与合适的前药结合的方法中用于治疗患者。一种治疗表达NQO2的靶细胞的人类患者的方法，其中该方法包括向患者注射一种前药，该前药通过NQO2和烟酰胺核苷酸（还原）（NRH）或其类似物的作用被转化为基本上具有细胞毒性的药物。
• [EN] PHOTOCHEMICAL SEPARATIONS AND COMPOSITIONS<br/>[FR] SÉPARATIONS PHOTOCHIMIQUES ET COMPOSITIONS
  申请人：UNIV FLORIDA STATE RES FOUND

  公开号：WO2019018735A1

  公开（公告）日：2019-01-24

  Provided herein are photochemical separations. The methods herein can include exposing a first metal complex and a second metal complex to light to facilitate an irreversible chemical reaction to form a modified first metal complex. The modified first metal complex then may be separated from the second metal complex. Compositions also are provided.

  本文提供了光化学分离方法。该方法包括将第一金属配合物和第二金属配合物暴露于光线下，以促进不可逆的化学反应，形成改性的第一金属配合物。然后可以将改性的第一金属配合物与第二金属配合物分离。同时，还提供了相应的组合物。
• Novel agents for replacement of NAD+/NADH system in enzymatic reactions
  申请人：——

  公开号：US20030022266A1

  公开（公告）日：2003-01-30

  Novel agents acting as co-factors for replacement of NAD(P) + /NAD(P)H co-enzyme systems in enzymatic oxido-reductive reactions. Agents mimicking the action of NAD(P) + /NAD(P)H system in enzymatic oxidation/reduction of substrates into reduced or oxidized products. A method for selection and preparation of the mimicking agents for replacement of NAD(P) + /NAD(P)H system and a device comprising co-factors for replacement of NAD(P) + /NAD(P)H system.

  新型药物作为辅因子，用于替代酶促氧化还原反应中的NAD(P)H/NAD(P)+辅酶系统。这些药物模仿NAD(P)H/NAD(P)+辅酶系统的作用，将底物在酶促氧化还原反应中转化为还原或氧化产物。本发明涉及一种选择和制备模仿剂以替代NAD(P)H/NAD(P)+辅酶系统的方法，以及包含辅因子的装置以替代NAD(P)H/NAD(P)+辅酶系统。
• Human quinone reductase 2 conjugates for ADEPT and GDEPT
  申请人：ENZACTA R & D LIMITED

  公开号：EP1468698A2

  公开（公告）日：2004-10-20

  A compound having formula I for use in medicine and, in particular, for the treatment of mammalian tumours. A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug.

  一种具有式 I 的化合物，用于医药，特别是用于治疗哺乳动物肿瘤。 一种化合物，包括靶细胞特异性部分和人 NAD(P)H：醌还原酶 2 (NQO2)或其变体或片段或融合体或衍生物，其对给定原药的活性与 NQO2 基本相同；或编码所述 NQO2 或所述变体或片段或融合体或衍生物的多核苷酸。 一种重组多核苷酸，其包含与编码人NAD(P)H:醌还原酶2 (NQO2)或其变体或片段或融合体或衍生物的多核苷酸可操作地连接的靶细胞特异性启动子，该多核苷酸对给定原药具有与NQO2基本相同的活性。 这些化合物和多核苷酸在与合适的原药一起治疗患者的方法中是有用的。